maintenance therapy

Type: Keyphrase
Name: maintenance therapy
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Genmab reports higher Q2 net loss, revises annual outlook

Genmab A/S, a biotechnology company, has reported that net loss for the second quarter ended June 30, 2014 was DKK26.15 million, or DKK0.46 loss per share, compared to a net loss of DKK25.34 million, or DKK0.50 loss per share, for the same quarter ended ... [Published Individual.com - 2 hours ago]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

how do I tell my coworkers that I have incurable cancer and it’s progressing?

A reader writes: I’m a 59-year-old professional woman with Stage 4, metastatic breast cancer; my original disease was diagnosed and treated in 1996, but multiple metastases emerged and were officially diagnosed in 2007. I received a very aggressive ... [Published Ask a Manager - Aug 28 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance [Global Data Point]

Interim Report First Half 2014?Announced three new Phase III studies of daratumumab in multiple myeloma and improved guidance twice?Achieved USD 25 million milestone payment under Janssen Biotech, Inc. collaboration for daratumumab?Arzerra (ofatumumab) ... [Published Pharmacy Choice - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 2 reports

Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance

; Copenhagen, Denmark;"We continue to make solid progress across our business as the year progresses. The label expansion for Arzerra to include treatment of first-line patients with CLL in the US in combination with chlorambucil in April was followed ... [Published Noodls - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Ambit Biosciences Announces Second Quarter 2014 Operating Results

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results ... [Published Bio-Medicine - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

[Articles] Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

Significant clinical benefit was seen at week 16 that increased with maintenance therapy. ... [Published The Lancet online - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Addicts need compassion — and treatment [Commentary]

On June 21, the Vatican press office published the presentation made by Pope Francis to the 31st International Drug Enforcement Conference (IDEC) in Rome. The pope told the conferees, "The problem of drug use is not solved with drugs! … Substitute drugs ... [Published Baltimore Sun - Aug 08 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Genmab announces positive interim result from Phase III CLL study analysis

GlaxoSmithKline plc, or GSK, and Genmab A/S, a biotechnology company, have announced that an Independent Data Monitoring Committee, or IDMC, interim analysis of a Phase III study, PROLONG, reached the predefined significance level for efficacy. The interim ... [Published Individual.com - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

The cost-effectiveness of treatment for opioid dependency

The following originally appeared on  The Upshot  (copyright 2014, The New York Times Company). Once  championed as the answer to chronic pain , opioid medications and painkillers have become a large and costly problem in the United States. Fatal overdoses ... [Published The Incidental Economist (Posts) - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Ulcerative Colitis

Ulcerative colitis (UC) is an inflammatory bowel disease affecting approximately 700,000 people in North America. 1 It is characterized by relapsing and remitting symptoms including rectal bleeding, diarrhea and abdominal pain. 1 Active UC symptoms can ... [Published Advance for NPs and PAs - Aug 06 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody

The use of an IL-3 inhibitor for prophylactic treatment of rheumatoid arthritis, for treatment of rheumatoid arthritis in an early stage, during early phases of exacerbation, or as maintenance therapy to prevent disease flares or disease progression in ... [Published Free Patents Online - Aug 05 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 2 reports

GlaxoSmithKline and Genmab report positive data from CLL drug trial

:07 in Pharmaceutical Company Product News GlaxoSmithKline and Genmab have announced that their drug ofatumumab has met its primary endpoint in a new efficacy trial for chronic lymphocytic leukaemia (CLL). An independent data monitoring committee has ... [Published Zenopa - Aug 05 2014]

Quotes

Jan van de Winkel, CEO of Genmab said: "We continue to make solid progress across our business as the year progresses. The label expansion for Arzerra to include treatment of first-line patients with CLL in the US in combination with chlorambucil in April was followed closely by approval in Europe for Arzerra in combination with chlorambucil or bendamustine. We were pleased to announce that the Phase III study of ofatumumab as maintenance therapy in relapsed CLL met its primary endpoint at an interim analysis. Furthermore, we announced three new Phase III studies of daratumumab in combination with backbone therapies, one in relapsed or refractory multiple myeloma and two in first line multiple myeloma. In July we reached a USD 25 million milestone based on progress in the first Phase III study under our collaboration with Janssen and have again been able to improve our financial guidance."
...advancements and choices in the treatment of patients with hematologic malignancies," said Robert W Carlson, MD, Chief Executive Officer, NCCN. "NCCN thanks the esteemed expert panel members, representing top cancer institutions throughout the country, for partaking in this annual event."
...However, as a result of the fact that fewer patients receive terminal diagnosis it is not an attractive area for research," Dr. Bunimovich said. "The quality of life during treatment however is unbearable, and the patient is often required to undergo surgery and many rounds of chemotherapy."
...QUANTUM-R PhasePhase 3 trial, our most notable achievement of the first half," said Michael Martino, Ambit's President and Chief Executive Officer. "The trial is progressing and sites continue to be activated on plan. This will remain our primary operating focus throughout the year. We are also pleased with the progress in multiple investigator- and company-sponsored studies that continue to suggest that quizartinib may be a workhorse in the broader fight against AML in newly diagnosed patients and as a maintenance therapy in patients after transplant. With QUANTUM-R underway, we are taking the next steps to execute this broader vision for quizartinib."

More Content

All (110) | News (94) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Genmab reports higher Q2 net loss, revises annu... [Published Individual.com - 2 hours ago]
Boehringer Ingelheim to present comprehensive d... [Published Scottrade - 4 hours ago]
A Practical Approach to Cutaneous Small-Vessel ... [Published General Medicine eJournal - 6 hours ago]
Long-term adalimumab therapy maintained remissi... [Published Orthopedics Today - Aug 29 2014]
CPE Monthly: Curcumin and Inflammatory Diseases [Published Today's Dietitian - Aug 28 2014]
how do I tell my coworkers that I have incurabl... [Published Ask a Manager - Aug 28 2014]
NCCN to Host 9th Annual Congress: Hematologic M... [Published The CW44 Tampa Bay - Aug 28 2014]
Agents for Atrial Fibrillation Prevention After... [Published General Medicine eJournal - Aug 28 2014]
Swiss researchers investigate drug use and its ... [Published CATIE - Aug 28 2014]
Addiction and survival with HIV [Published CATIE - Aug 26 2014]
Data on Celgene's Revlimid Published in Oncolog... [Published Yahoo! Finance - Aug 22 2014]
Metastatic Colorectal Cancer: Update Now Shows ... [Published Oncology Times - Aug 22 2014]
Woman's Cancer Drives Daughter To Research Brea... [Published Virtual Jerusalem - Aug 21 2014]
No Tumor-Free Waiting Period after Treatment of... [Published Sexual Development - Aug 21 2014]
Anti-infliximab antibodies associated with trea... [Published Orthopedics Today - Aug 19 2014]
Carcinoma of Unknown Primary Site Treated with ... [Published Sexual Development - Aug 19 2014]
Ambit Biosciences Releases 2Q 2014 Results [Published Individual.com - Aug 18 2014]
What is the correct diagnosis and how should it... [Published Medicine Today - Aug 17 2014]
A Pharmacogenetics-Based Warfarin Maintenance D... [Published Plosone.org - Aug 16 2014]
Selected Patients With Lung Cancer and Poor Per... [Published The ASCO Post - Aug 15 2014]
Periodontal disease starts painlessly, so don’t... [Published Community Voice - Aug 15 2014]
Genmab Announces Financial Results for the Firs... [Published Pharmacy Choice - Aug 14 2014]
Predicting Resistance by Selection of Signaling... [Published General Medicine eJournal - Aug 14 2014]
Genmab's (GNMSF) CEO Jan Winkel on Q2 2014 Resu... [Published Seeking Alpha - Aug 14 2014]
Patent Issued for Device and Implantation Syste... [Published 4 Traders - Aug 14 2014]
Genmab Announces Financial Results for the Firs... [Published Noodls - Aug 13 2014]
Genmab Announces Financial Results for the Firs... [Published Virtual Strategy Magazine - Aug 13 2014]
Genmab Announces Financial Results for the Firs... [Published SPi World News - Aug 13 2014]
Genmab Announces Financial Results for the Firs... [Published GlobeNewswire: Acquisitions News - Aug 13 2014]
Ambit Biosciences' (AMBI) CEO Mike Martino on Q... [Published Seeking Alpha - Aug 13 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
how do I tell my coworkers that I have incurabl... [Published Ask a Manager - Aug 28 2014]
A reader writes: I’m a 59-year-old professional woman with Stage 4, metastatic breast cancer; my original disease was diagnosed and treated in 1996, but multiple metastases emerged and were officially diagnosed in 2007. I received a very aggressive ...
[Articles] Oral ponesimod in patients with chro... [Published The Lancet online - Aug 11 2014]
Significant clinical benefit was seen at week 16 that increased with maintenance therapy. ...
The cost-effectiveness of treatment for opioid ... [Published The Incidental Economist (Posts) - Aug 06 2014]
The following originally appeared on  The Upshot  (copyright 2014, The New York Times Company). Once  championed as the answer to chronic pain , opioid medications and painkillers have become a large and costly problem in the United States. Fatal overdoses ...
BiologicTx® Selected As The Specialty Pharmacy ... [Published PR Newswire: Health - Jul 17 2014]
TOTOWA, N.J., July 17, 2014 /PRNewswire/ -- BiologicTx® was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on ...
RheumShorts: Vasculitis, MRI, Anakinra for Knee... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 29 2014]
(MedPage Today) -- The rheumatology literature this week explored whether or not patients with vasculitis treated with rituximab also need maintenance therapy, if MRI can predict later arthritis when disease is still subclinical, and how an interleukin ...
1 2 3

Press Releases

sort by: Date | Relevance
Genmab Announces Financial Results for the Firs... [Published GlobeNewswire: Acquisitions News - Aug 13 2014]
Positive Top-line Results from Two Phase 3 Clin... [Published GlobeNewswire: Advertising News - Jun 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.